Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) comprises the majority (~85%) of all lung tumors, with lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) being the most frequently diagnosed histological subtypes. Multi-modal omics profiling has been carried out in NSCLC, but no studies have yet reported a unique metabolite-related gene signature and altered metabolic pathways associated with LUAD and LUSC.

Methods

We integrated transcriptomics and metabolomics to analyze 30 human lung tumors and adjacent noncancerous tissues. Differential co-expression was used to identify modules of metabolites that were altered between normal and tumor.

Results

We identified unique metabolite-related gene signatures specific for LUAD and LUSC and key pathways aberrantly reg

SUBMITTER: Thaiparambil J 

PROVIDER: S-EPMC9844651 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature